Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/177731
Title: | Immunosuppression minimization in kidney transplant recipients hospitalized for COVID-19 |
Author: | Anton Pampols, Paula Trujillo, Hernando Melilli, Edoardo Urban, Blanca Sandino, Justo Favà Buch, Alexandre Gutierrez, Eduardo Bestard Matamoros, Oriol Mancebo, Esther Sevillano, Angel Cruzado, Josep Ma. Morales, Enrique |
Keywords: | Immunosupressors COVID-19 Trasplantament renal Immunosupressive agents COVID-19 Kidney transplantation |
Issue Date: | 29-Jan-2021 |
Publisher: | Oxford University Press |
Abstract: | Background. Immunosuppressed patients such as kidney transplant recipients (KTs) have increased mortality risk in the setting of coronavirus disease 2019 (COVID-19). The role and management of chronic immunosuppressive therapies during COVID-19 must be characterized. Methods. Herein, we report the follow-up of a cohort of 47 KTs admitted at two Spanish Kidney Transplant Units, who survived COVID-19. The impact of the management of immunosuppression during COVID-19 on graft function and immunologic events was evaluated. Results. At least one immunosuppressive agent was withdrawn in 83% of patients, with antimetabolites being the most frequent. Steroids were generally not stopped and the dose was even increased in 15% of patients as part of the treatment of COVID-19. Although immunosuppressive drugs were suspended during a median time of 17 days, no rejection episodes or de novo donorspecific antibodies were observed up to 3 months after discharge, and no significant changes occurred in calculated panel reactive antibodies. Acute graft dysfunction was common (55%) and the severity was related to tacrolimus trough levels, which were higher in patients receiving antivirals. At the end of follow-up, all patients recovered baseline kidney function. Conclusions. Our observational study suggests that immunosuppression in KTs hospitalized due to COVID-19 could be safely minimized. |
Note: | Reproducció del document publicat a: https://doi.org/10.1093/ckj/sfab025 |
It is part of: | Clinical Kidney Journal, 2021, vol. 14, num. 4, p. 1229-1235 |
URI: | http://hdl.handle.net/2445/177731 |
Related resource: | https://doi.org/10.1093/ckj/sfab025 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
sfab025.pdf | 1.83 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License